ATE446372T1 - Vesikuläre komplexe und verfahren zu deren herstellung und verwendung - Google Patents

Vesikuläre komplexe und verfahren zu deren herstellung und verwendung

Info

Publication number
ATE446372T1
ATE446372T1 AT98920077T AT98920077T ATE446372T1 AT E446372 T1 ATE446372 T1 AT E446372T1 AT 98920077 T AT98920077 T AT 98920077T AT 98920077 T AT98920077 T AT 98920077T AT E446372 T1 ATE446372 T1 AT E446372T1
Authority
AT
Austria
Prior art keywords
disclosed
individuals
methods
production
cells
Prior art date
Application number
AT98920077T
Other languages
German (de)
English (en)
Inventor
Richard Ciccarelli
C Satishchandran
Catherine Pachuk
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE446372T1 publication Critical patent/ATE446372T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/905—Specially adapted for travel through blood circulatory system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98920077T 1997-04-30 1998-04-30 Vesikuläre komplexe und verfahren zu deren herstellung und verwendung ATE446372T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4512297P 1997-04-30 1997-04-30
PCT/US1998/008799 WO1998048780A1 (en) 1997-04-30 1998-04-30 Vesicular complexes and methods of making and using the same

Publications (1)

Publication Number Publication Date
ATE446372T1 true ATE446372T1 (de) 2009-11-15

Family

ID=21936112

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98920077T ATE446372T1 (de) 1997-04-30 1998-04-30 Vesikuläre komplexe und verfahren zu deren herstellung und verwendung

Country Status (12)

Country Link
US (2) US6217900B1 (enExample)
EP (1) EP0986372B1 (enExample)
JP (1) JP2002508747A (enExample)
KR (1) KR100554344B1 (enExample)
CN (1) CN1092045C (enExample)
AT (1) ATE446372T1 (enExample)
AU (1) AU728115C (enExample)
BR (1) BR9809006B1 (enExample)
CA (1) CA2285298C (enExample)
DE (1) DE69841251D1 (enExample)
ES (1) ES2333282T3 (enExample)
WO (1) WO1998048780A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69942581D1 (de) * 1998-05-25 2010-08-26 Nippon Shinyaku Co Ltd Verfahren zur herstellung einer nucleinsäure enthaltenden kompositzusammenstellung
CA2361201A1 (en) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
EP1097993A3 (en) * 1999-11-05 2004-01-07 National Institute of Advanced Industrial Science and Technology Functional ribozyme chimeric molecules capable of sliding
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2474822A1 (en) * 2002-02-07 2003-08-14 University Of Utah Research Foundation Method for creating and using a treatment protocol
US20040180438A1 (en) * 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
JP4868739B2 (ja) * 2002-05-06 2012-02-01 アルナイラム ファーマシューティカルズ， インコーポレイテッド 核酸の送達法
JP2005529959A (ja) * 2002-06-14 2005-10-06 マイラス コーポレイション 細胞へのポリヌクレオチドの伝達をするための新規な方法
WO2004011624A2 (en) * 2002-07-31 2004-02-05 Nucleonics, Inc. Double stranded rna structures and constructs, and methods for generating and using the same
WO2004073631A2 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
CA3040025C (en) 2003-06-12 2023-01-10 Alnylam Pharmaceuticals, Inc. Conserved hbv and hcv sequences useful for gene silencing
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
EP2325314B1 (en) 2004-09-24 2014-08-20 Alnylam Pharmaceuticals, Inc. Targeting opposite strand replication intermediates of single-stranded viruses by RNAI
AU2005319306B9 (en) 2004-12-22 2012-04-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
PT1912675E (pt) 2005-07-25 2014-05-09 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
MX380352B (es) 2006-06-12 2025-03-12 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
CN101541950A (zh) 2006-07-13 2009-09-23 惠氏公司 糖蛋白的产生
DK2548438T3 (en) 2006-11-08 2015-10-19 Veritas Bio LLC IN VIVO SUBMITTING DOUBLE-STRENGTH RNA TO A CELL
CN101990439A (zh) * 2007-07-06 2011-03-23 特鲁比昂药品公司 具有置于c末端的特异性结合结构域的结合肽
RS51975B (sr) 2008-04-11 2012-02-29 Emergent Product Development Seattle Llc. Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom
CA2761106C (en) 2009-05-05 2019-01-15 Miragen Therapeutics Lipophilic polynucleotide conjugates
AU2010258875A1 (en) 2009-06-08 2012-01-19 Miragen Therapeutics Chemical modification motifs for miRNA inhibitors and mimetics
NZ602538A (en) * 2010-04-01 2014-03-28 Pharmanest Ab Thermogelling anaesthetic compositions
EP2635681B8 (en) 2010-11-05 2017-10-04 Miragen Therapeutics, Inc. Base modified oligonucleotides
AR084319A1 (es) 2010-12-15 2013-05-08 Miragen Therapeutics INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS
AU2012242761A1 (en) 2011-04-12 2013-10-31 Beth Israel Deaconess Medical Center, Inc. Micro-RNA inhibitors and their uses in disease
US9018188B2 (en) 2011-09-13 2015-04-28 Ottawa Hospital Research Institute MicroRNA inhibitors
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
CA2902571A1 (en) 2013-03-15 2014-09-18 MiRagen Therapeutics, Inc. Bridged bicyclic nucleosides
US10172916B2 (en) 2013-11-15 2019-01-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
US10772974B2 (en) 2013-11-18 2020-09-15 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for cardiac regeneration
JP6637961B2 (ja) 2014-08-04 2020-01-29 ミラゲン セラピューティクス， インコーポレイテッド Ｍｙｈ７ｂの阻害剤およびその使用
JP6837963B2 (ja) 2014-09-08 2021-03-03 ミラゲン セラピューティクス， インコーポレイテッド Ｍｉｒ−２９模倣物およびその使用
JP2018503646A (ja) 2015-01-20 2018-02-08 ミラゲン セラピューティクス， インコーポレイテッド ｍｉＲ−９２阻害剤およびその使用
WO2016197024A2 (en) 2015-06-05 2016-12-08 MiRagen Therapeutics, Inc. Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl)
BR112018005573A2 (pt) 2015-09-21 2019-01-22 Aptevo Research And Development Llc ?polipeptídeos de ligação a cd3?
US10357543B2 (en) 2015-11-16 2019-07-23 Ohio State Innovation Foundation Methods and compositions for treating disorders and diseases using Survival Motor Neuron (SMN) protein
NZ749593A (en) 2016-06-20 2025-10-31 Univ Leland Stanford Junior Circular rnas and their use in immunomodulation
UY37376A (es) 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
ES2659845B1 (es) 2016-09-19 2019-01-04 Univ Valencia Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello
UY38003A (es) 2017-12-12 2019-06-28 Amgen Inc Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas
EP3765619B1 (en) 2018-03-14 2024-10-09 Beth Israel Deaconess Medical Center Inhibitors of micro-rna 22
KR20210102932A (ko) 2018-12-10 2021-08-20 암젠 인크 Pnpla3 발현을 억제하기 위한 rnai 작제물 및 이의 사용 방법
JP2022511866A (ja) 2018-12-10 2022-02-01 アムジエン・インコーポレーテツド 化学修飾されたＲＮＡｉコンストラクト及びその使用
TW202111124A (zh) 2019-05-30 2021-03-16 美商安進公司 用於抑制ｓｃａｐ表現之ｒｎａｉ構建體及其使用方法
CA3150758A1 (en) 2019-08-13 2021-02-18 Amgen Inc. Rnai constructs for inhibiting slc30a8 expression and methods of use thereof
US20230078200A1 (en) 2019-12-09 2023-03-16 Amgen Inc. RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
WO2021234607A1 (en) 2020-05-20 2021-11-25 St. Jude Children's Research Hospital Detection of alzheimer's disease using specific biomarkers
US20230279399A1 (en) 2020-06-01 2023-09-07 Amgen Inc. Rnai constructs for inhibiting hsd17b13 expression and methods of use thereof
EP3929295A1 (en) 2020-06-26 2021-12-29 Universitat Pompeu Fabra Artificial rnas for modulating rna fragments
CR20230126A (es) 2020-08-13 2023-05-03 Amgen Inc CONSTRUCCIONES DE iARN Y MÉTODOS PARA INHIBIR LA EXPRESIÓN DE MARC1
KR20230104200A (ko) 2020-11-05 2023-07-07 암젠 인크 LPA-표적화된 RNAi 작제물을 이용하여 죽상경화성 심혈관질환을 치료하는 방법
WO2023278295A1 (en) 2021-06-29 2023-01-05 The Broad Institute, Inc. Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability
CA3234369A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Compositions and methods for enhancing gene silencing activity of oligonucleotide compounds
WO2023069754A2 (en) 2021-10-22 2023-04-27 Amgen Inc. Rnai constructs for inhibiting gpam expression and methods of use thereof
IL317825A (en) 2022-07-25 2025-02-01 Amgen Inc RNA interference constructs and methods for inhibiting fam13a expression
EP4353823A1 (en) 2022-10-12 2024-04-17 Resalis Therapeutics S.r.l. Inhibitors of micro-rna 22
IL321194A (en) 2022-12-16 2025-07-01 Amgen Inc RNA interference constructs for inhibiting TTR expression and methods for using them
WO2025260042A1 (en) 2024-06-14 2025-12-18 Amgen Inc. Rnai constructs and methods for inhibiting cnr1 expression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5948441A (en) * 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
US5514788A (en) 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
DE69434469T2 (de) * 1993-01-26 2006-06-14 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
WO1996021015A2 (en) * 1994-12-30 1996-07-11 Chiron Corporation Combination gene delivery vehicles
KR20140137679A (ko) 2013-05-23 2014-12-03 삼성전자주식회사 카드 소켓 장치

Also Published As

Publication number Publication date
KR100554344B1 (ko) 2006-02-22
ES2333282T3 (es) 2010-02-18
BR9809006B1 (pt) 2010-02-09
AU728115C (en) 2004-01-22
DE69841251D1 (de) 2009-12-03
US6217900B1 (en) 2001-04-17
AU7272498A (en) 1998-11-24
KR20010020161A (ko) 2001-03-15
CA2285298C (en) 2008-12-23
AU728115B2 (en) 2001-01-04
EP0986372A1 (en) 2000-03-22
BR9809006A (pt) 2000-08-08
WO1998048780A1 (en) 1998-11-05
CA2285298A1 (en) 1998-11-05
JP2002508747A (ja) 2002-03-19
EP0986372B1 (en) 2009-10-21
CN1277549A (zh) 2000-12-20
CN1092045C (zh) 2002-10-09
US6383512B1 (en) 2002-05-07
EP0986372A4 (en) 2002-06-19

Similar Documents

Publication Publication Date Title
DE69841251D1 (de) Vesikuläre komplexe und verfahren zu deren herstellung und verwendung
DE69713336D1 (de) Verfahren zur Herstellung von aktivierten markierten tumorspezifischen T-Zellen und deren Verwendung in der Behandlung von Tumoren
ATE316333T1 (de) Verfahren zur in-vivo abgabe therapeutischer agenzien mittels liposomen
DE69429915D1 (de) Verfahren zur Herstellung von Leistungsbauteilen hoher Dichte in MOS-Technologie
PL319833A1 (en) Compounds and composition for carrying active media
ATE370960T1 (de) Verknüpfte peptid-nukleinsäuren
BR9607273A (pt) Molécula de dna duplo filamento dna recombinante plasmídio célula recombinante composiçao farmacéutica e processo de preparaçao de uma molécula de dna
DE69302971D1 (de) Antiperkolation Gasdiffusionselektrode und Verfahren zur deren Herstellung
DE69840932D1 (de) Zusammensetzungen und verfahren zur verstärkung der verabreichung von therapeutischen mitteln in zellen
ATE253836T1 (de) Geschmacksverstärkende n-ethyl-p-menthan-3- carboxamid enthaltende zusammensetzungen und verfahren zu deren herstellung und verwendung
ATE181361T1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
DE69809091D1 (de) Phenylphosphonsäurederivate und deren Herstellung
FI964582L (fi) Aminosulfonihappojohdannaisia, niiden käyttö pseudopeptidisynteesissä ja menetelmä niiden valmistamiseksi
ATE140455T1 (de) Neue 2-amino-5-cyano-1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE69531881D1 (de) Ionenempfindliche Elektrode und Verfahren zur Herstellung von Ionenempfindlichen Elektroden
EP0770137A4 (en) IMPROVEMENTS IN PROTEIN PRODUCTION IN HOST CELLS
DE69318624D1 (de) Aminogruppen-enthaltende Organipolysiloxane und Verfahren zur deren Herstellung
ATE242335T1 (de) Population von mit myeloid-und/oder lymphoid- vorläufern angereicherten zellen und verfahren zur ihrer gewinnung und verwendung
DE3577443D1 (de) Derivate von dihydroorotsaeure, deren verfahren zur herstellung und deren pharmazeutische zusammensetzungen.
DE69611438D1 (de) Bizyclische tachykinin-antagonisten, deren herstellung und deren verwendung in pharmazeutischen zusammmensetzungen
DK0977859T3 (da) Den neurotrofiske faktor NNT-1
DE69624953D1 (de) Kosmetika in Stiftform und Verfahren zu deren Herstellung
AT386417B (de) Verfahren zur herstellung von selbstvernetzenden kationischen lackbindemitteln und deren verwendungin wasserverduennbaren lacken
DE69507206D1 (de) Trifluor-2-(4-Trans-substituierte Cyclohexyl) und Verfahren zu deren Herstellung
DE3861271D1 (de) Basisch substituierte benzofurancarbonsaeureamide, verfahren zu ihrer herstellung und sie enthaltende therapeutische mittel.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties